Every dated clinical binary — an FDA PDUFA decision or a Phase 2/3 readout — priced against the options chain: the straddle over the expiry bracketing the event vs the stock's own realized-vol baseline. 61 priced · Aug 15, 9:17 PM
What this is: the binary-event calendar from Biotech Catalysts, but priced. For each upcoming FDA decision or trial readout, we price the at-the-money straddle to the expiry that brackets the event.
Implied move = that straddle ÷ the stock price — how big a move the options market is pricing for the binary. Baseline = the stock's own realized-vol move over the same window (what it'd do on ordinary vol, no event).
Event premium = implied ÷ baseline. Unlike an investor day, a real biotech binary is expected to move big — so the read is relative: we rank each event's premium against the whole biotech cohort. Options light = the market is loading the binary the least (cheap optionality if you believe it's make-or-break); fully loaded = richly priced.
Caveat: mega-cap pharma (a single trial isn't material) will always look "light"; the signal is sharpest on single-asset small-caps. Dates are estimates from public filings; not advice.
| Ticker | Event | Date | Implied ± | Baseline ± | Premium | Read |
|---|---|---|---|---|---|---|
| BMY BRISTOL MYERS SQUIBB CO | PDUFA Iberdomide | Aug 17, 2026 in 2d | ±3% | ±3% | 0.80× | options light |
| MRK Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | Phase 2 Ensifentrine 3 mg · Chronic Obstructive Pulmonary Disease | Aug 17, 2026 in 2d | ±3% | ±3% | 0.94× | fair |
| MRK Merck Sharp & Dohme LLC | Phase 1/Phase 2 Pembrolizumab · Carcinoma, Renal Cell | Aug 21, 2026 in 6d | ±3% | ±3% | 0.94× | fair |
| CAPR CAPRICOR THERAPEUTICS, INC. | PDUFA Deramiocel · Duchenne muscular dystrophy | Aug 22, 2026 in 7d | ±59% | ±108% | 0.54× | options light |
| RARE Ultragenyx Pharmaceutical Inc. | PDUFA DTX401 (pariglasgene brecaparvovec) · glycogen storage disease type Ia (GSDIa) | Aug 23, 2026 in 8d | ±35% | ±13% | 2.67× | fully loaded |
| REGN Regeneron Pharmaceuticals | Phase 2 Fianlimab · Resectable Non-small Cell Lung Cancer | Aug 24, 2026 in 9d | ±4% | ±6% | 0.74× | options light |
| ZYME Zymeworks Inc. | PDUFA zanidatamab · first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesoph | Aug 25, 2026 in 10d | ±23% | ±12% | 1.84× | fully loaded |
| JAZZ Jazz Pharmaceuticals plc | PDUFA zanidatamab · first-line (1L) gastroesophageal adenocarcinoma (GEA) | Aug 25, 2026 in 10d | ±10% | ±8% | 1.27× | fully loaded |
| IRDM Disc Medicine, Inc | Phase 3 Placebo · Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP) | Sep 1, 2026 in 17d | ±9% | ±11% | 0.84× | options light |
| VNDA Vanda Pharmaceuticals | Phase 3 Tasimelteon · Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm | Sep 1, 2026 in 17d | ±15% | ±13% | 1.14× | fully loaded |
| LLY Eli Lilly and Company | Phase 3 LY3650150 · Perennial Allergic Rhinitis (PAR) | Sep 1, 2026 in 17d | ±6% | ±8% | 0.74× | options light |
| TEVA Teva Branded Pharmaceutical Products R&D LLC | Phase 2 TEV-53408 · Celiac Disease | Sep 15, 2026 in 31d | ±8% | ±12% | 0.65× | options light |
| IONS IONIS PHARMACEUTICALS INC | PDUFA zilganersen · Alexander disease | Sep 22, 2026 in 38d | ±15% | ±37% | 0.42× | options light |
| NVS Novartis Pharmaceuticals | Phase 1/Phase 2 YTB323 · Systemic Lupus Erythematosus, Lupus Nephritis | Sep 24, 2026 in 40d | ±9% | ±9% | 1.02× | fully loaded |
| MIRM Mirum Pharmaceuticals, Inc. | PDUFA zilurgisertib · fibrodysplasia ossificans progressiva (FOP) | Sep 26, 2026 in 42d | ±24% | ±22% | 1.06× | fully loaded |
| OCGN Ocugen | Phase 2/Phase 3 OCU410ST · Stargardt Disease | Sep 28, 2026 in 44d | ±48% | ±19% | 2.55× | fully loaded |
| SRRK Scholar Rock Holding Corp | PDUFA apitegromab · spinal muscular atrophy (SMA) | Sep 30, 2026 in 46d | ±23% | ±21% | 1.09× | fully loaded |
| MIRM Mirum Pharmaceuticals, Inc. | Phase 3 Maralixibat · Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | Oct 1, 2026 in 47d | ±24% | ±22% | 1.06× | fully loaded |
| ABBV AbbVie | Phase 3 Aflibercept (EYLEA®) · AMD, nAMD | Oct 1, 2026 in 47d | ±8% | ±9% | 0.90× | fair |
| INCY Incyte Corporation | Phase 3 Ruxolitinib Cream · Hidradenitis Suppurativa | Oct 9, 2026 in 55d | ±17% | ±20% | 0.86× | fair |
| SLDB Solid Biosciences Inc. | Phase 1/Phase 2 Microdystrophin Gene Transfer Study in Adolescents and Children With DMD · Duchenne Muscular Dystrophy | Oct 15, 2026 in 61d | ±51% | ±31% | 1.64× | fully loaded |
| BIIB Biogen | Phase 2/Phase 3 Litifilimab · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus | Oct 20, 2026 in 66d | ±17% | ±26% | 0.65× | options light |
| BMY Mirati Therapeutics Inc. | Phase 2 Adagrasib · Advanced Cancer, Metastatic Cancer | Oct 30, 2026 in 76d | ±14% | ±17% | 0.86× | fair |
| VRTX Vertex Pharmaceuticals Incorporated | Phase 3 VX-121/TEZ/D-IVA · Cystic Fibrosis | Oct 30, 2026 in 76d | ±14% | ±17% | 0.82× | options light |
| OLMA Olema Pharmaceuticals, Inc. | Phase 3 Palazestrant · Breast Cancer, Advanced Breast Cancer | Oct 31, 2026 in 77d | ±46% | ±33% | 1.41× | fully loaded |
| AGIO AGIOS PHARMACEUTICALS, INC. | PDUFA mitapivat · sickle cell disease | Nov 1, 2026 in 78d | ±28% | ±35% | 0.79× | options light |
| APGE Apogee Therapeutics, Inc. | Phase 2 APG777 · Atopic Dermatitis | Nov 1, 2026 in 78d | ±4% | ±1% | 3.35× | fully loaded |
| AZN AstraZeneca | Phase 3 Trastuzumab deruxtecan · Breast Cancer; HER2-positive; Metastatic | Nov 11, 2026 in 88d | ±15% | ±24% | 0.62× | options light |
| SMMT Summit Therapeutics Inc. | PDUFA ivonescimab · EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung ca | Nov 14, 2026 in 91d | ±56% | ±42% | 1.31× | fully loaded |
| BBIO BridgeBio Pharma, Inc. | PDUFA BBP-418 · LGMD2I/R9 | Nov 27, 2026 in 104d | ±24% | ±33% | 0.73× | options light |
| RPRX Royalty Pharma plc | PDUFA neladalkib · non-small cell lung cancer | Nov 27, 2026 in 104d | ±11% | ±14% | 0.83× | options light |
| COGT Cogent Biosciences, Inc. | PDUFA bezuclastinib | Nov 30, 2026 in 107d | ±44% | ±35% | 1.27× | fully loaded |
| ZLAB Zai Lab Ltd | PDUFA povetacicept (pove) · immunoglobulin A nephropathy (IgAN) | Nov 30, 2026 in 107d | ±43% | ±38% | 1.15× | fully loaded |
| VRTX VERTEX PHARMACEUTICALS INC / MA | PDUFA povetacicept | Nov 30, 2026 in 107d | ±14% | ±17% | 0.82× | options light |
| CORT Corcept Therapeutics | Phase 2 relacorilant · Cushing Syndrome | Dec 1, 2026 in 108d | ±34% | ±54% | 0.64× | options light |
| PRAX Praxis Precision Medicines | Phase 3 1.0mg/kg/day PRAX-562 · Developmental and Epileptic Encephalopathy 1 | Dec 1, 2026 in 108d | ±37% | ±38% | 0.98× | fully loaded |
| EXEL EXELIXIS, INC. | PDUFA zanzalintinib (in combination with atezolizumab) · metastatic colorectal cancer (previously treated with fluoropyrimidine-, oxalipl | Dec 3, 2026 in 110d | ±18% | ±23% | 0.77× | options light |
| VNDA Vanda Pharmaceuticals Inc. | PDUFA Quimilza (imsidolimab) · Generalized Pustular Psoriasis (GPP) | Dec 12, 2026 in 119d | ±43% | ±26% | 1.64× | fully loaded |
| BMY Bristol-Myers Squibb | Phase 2 BMS-986435 · Heart Failure | Dec 14, 2026 in 121d | ±14% | ±17% | 0.86× | fair |
| CORT CORCEPT THERAPEUTICS INC | PDUFA relacorilant · Cushing's syndrome | Dec 17, 2026 in 124d | ±34% | ±55% | 0.63× | options light |
| MLYS Mineralys Therapeutics, Inc. | PDUFA lorundrostat · hypertension in combination with other antihypertensive drugs | Dec 22, 2026 in 129d | ±45% | ±23% | 1.97× | fully loaded |
| JNJ Janssen Pharmaceutica N.V., Belgium | Phase 2 JNJ-64042056 · Alzheimer Disease | Dec 22, 2026 in 129d | ±13% | ±15% | 0.86× | fair |
| VTRS Viatris Inc | PDUFA MR-107A-02 (fast-acting meloxicam) · moderate-to-severe acute pain | Dec 27, 2026 in 134d | ±17% | ±22% | 0.76× | options light |
| PFE Pfizer | Phase 3 PF-06821497 · Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Dec 28, 2026 in 135d | ±11% | ±13% | 0.86× | fair |
| JNJ Janssen Research & Development, LLC | Phase 3 Cetrelimab · Urinary Bladder Neoplasms | Dec 30, 2026 in 137d | ±13% | ±15% | 0.86× | fair |
| AMGN Amgen | Phase 1/Phase 2 AMG 732 · Thyroid Eye Disease | Jan 6, 2027 in 144d | ±14% | ±17% | 0.83× | options light |
| INCY Incyte Corporation | Phase 1/Phase 2 INCA034176 · Chronic Graft-versus-host-disease | Jan 6, 2027 in 144d | ±19% | ±22% | 0.85× | fair |
| AZN AstraZeneca | Phase 3 Placebo (blinded) · Systemic Sclerosis, Scleroderma | Jan 6, 2027 in 144d | ±15% | ±24% | 0.62× | options light |
| DYN Dyne Therapeutics, Inc. | PDUFA z-rostudirsen | Jan 21, 2027 in 159d | ±58% | ±30% | 1.96× | fully loaded |
| PRAX Praxis Precision Medicines, Inc. | PDUFA ulixacaltamide HCl · Essential Tremor | Jan 29, 2027 in 167d | ±47% | ±46% | 1.03× | fully loaded |
| PFE Seagen, a wholly owned subsidiary of Pfizer | Phase 3 disitamab vedotin · Urothelial Carcinoma | Jan 29, 2027 in 167d | ±14% | ±16% | 0.89× | fair |
| GMAB Genmab | Phase 3 Rina-S · Platinum-resistant Ovarian Cancer | Feb 1, 2027 in 170d | ±42% | ±24% | 1.76× | fully loaded |
| JNJ Janssen Research & Development, LLC | Phase 3 Guselkumab Subcutaneous · Colitis, Ulcerative | Feb 10, 2027 in 179d | ±15% | ±18% | 0.85× | fair |
| SNY Sanofi | Phase 3 Itepekimab (SAR440340) · Chronic Rhinosinusitis With Nasal Polyps | Feb 17, 2027 in 186d | ±16% | ±18% | 0.89× | fair |
| BMRN BIOMARIN PHARMACEUTICAL INC | PDUFA VOXZOGO · achondroplasia | Feb 28, 2027 in 197d | ±40% | ±44% | 0.91× | fair |
| NVO Novo Nordisk A/S | Phase 3 CagriSema (Cagrilintide B and Semaglutide I) · Obesity | Mar 1, 2027 in 198d | ±22% | ±32% | 0.69× | options light |
| MRNA ModernaTX, Inc. | Phase 2 mRNA-1647 · Cytomegalovirus Infection | Mar 6, 2027 in 203d | ±50% | ±53% | 0.94× | fair |
| NVS Novartis Pharmaceuticals | Phase 3 Ianalumab · Systemic Lupus Erythematosus | Mar 24, 2027 in 221d | ±18% | ±20% | 0.91× | fair |
| VRTX Vertex Pharmaceuticals Incorporated | Phase 3 ELX/TEZ/IVA · Cystic Fibrosis | Apr 6, 2027 in 234d | ±24% | ±27% | 0.89× | fair |
| NVS Novartis Pharmaceuticals | Phase 3 ianalumab · Systemic Lupus Erythematosus | Apr 12, 2027 in 240d | ±18% | ±20% | 0.91× | fair |
| AMGN Amgen | Phase 3 Ocrelizumab (US) · Relapsing-remitting Multiple Sclerosis (RRMS) | Apr 19, 2027 in 247d | ±21% | ±25% | 0.84× | options light |